Non-Insulin Therapies For Diabetes Global Market Report 2024

Non-insulin therapies for diabetes are treatments and medications designed to manage blood sugar levels in diabetic patients without the need for insulin injections. These therapies play a crucial role in regulating blood glucose levels for patients who either do not require insulin or prefer alternative methods of treatment.

The primary classes of drugs in the non-insulin therapies for diabetes market include biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides, for instance, are oral hypoglycemic agents that target type 2 diabetes by reducing liver glucose production and improving insulin sensitivity. These medications can be administered orally or intramuscularly and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies. They are utilized for purposes such as monitoring, diagnosis, treatment, and more.

The non-insulin therapies for diabetes market research report is one of a series of new reports that provides non-insulin therapies for diabetes market statistics, including the non-insulin therapies for diabetes industry global market size, regional shares, competitors with non-insulin therapies for diabetes market share, detailed non-insulin therapies for diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. These non-insulin therapies for diabetes market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $18.71 billion in 2023 to $19.98 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. Historical growth factors in the non-insulin therapies for diabetes market include the growing prevalence of diabetes, heightened awareness regarding diabetes management, increased healthcare spending, lifestyle changes contributing to higher incidence rates, a rise in diagnoses, government initiatives promoting diabetes care, and greater investment in pharmaceutical research and development.

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $26.14 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. Anticipated growth drivers in the forecast period for non-insulin therapies for diabetes comprise the rising prevalence of diabetes, heightened awareness of diabetes management, increased adoption of combination therapies, expansion of the geriatric population, growing healthcare expenditure, the proliferation of telemedicine, and a growing preference for oral medications. Major trends expected in this period include advancements in oral and injectable medications, innovations in drug delivery systems, progress in oral peptide delivery methods, widespread adoption of telemedicine and digital health solutions, and advancements in combination therapies.

The rising prevalence of diabetes is expected to drive the growth of non-insulin therapies in the diabetes market. Diabetes is a chronic condition characterized by elevated blood glucose levels, resulting from insufficient insulin production or improper insulin utilization by the body. Factors contributing to the increasing cases of diabetes include sedentary lifestyles, unhealthy diets, genetic factors, aging populations, obesity, ethnicities, lack of awareness, limited healthcare access, and environmental influences. Non-insulin therapies target diabetes by improving insulin sensitivity, reducing liver glucose production, enhancing glucose uptake in muscle cells, and overall glycemic control. For example, in 2021, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 were living with diabetes globally. This number is projected to reach 643 million by 2030 and 783 million by 2045, highlighting the growth trajectory of diabetes cases and the consequent demand for non-insulin therapies.

Leading companies in the non-insulin therapies market are focusing on personalized diabetes management systems to improve patient outcomes through real-time monitoring, data analysis, and customized treatment plans. Personalized systems adapt treatment strategies and monitoring based on individual patient needs, leveraging real-time data and analytics to optimize care. For instance, Eli Lilly and Company introduced the Tempo personalized diabetes management platform in November 2022. This platform integrates the Tempo Smart Button, TempoSmart app, and prefilled insulin pen (Tempo Pen) to deliver tailored guidance for adults with diabetes. The technology assists both type 1 and type 2 diabetes patients and their healthcare providers in making informed, data-driven treatment decisions using Lilly insulins.

In August 2023, Eli Lilly and Company acquired Sigilon Therapeutics Inc. for $309.6 million, enhancing its research and development efforts in encapsulated cell therapies such as SIG-002 for type 1 diabetes treatment. This acquisition reflects Lilly's commitment to advancing solutions that alleviate the continuous disease management burden for individuals with type 1 diabetes. Sigilon Therapeutics Inc. is a biopharmaceutical company specializing in encapsulated cell therapies for type 1 diabetes treatment.

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC.

North America was the largest region in the non-insulin therapies for diabetes market in 2023. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-insulin therapies for diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.